Greenwoods Asset Management Ltd continued to hold its position in China Biologic Products, Inc. (NASDAQ:CBPO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,500 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. China Biologic Products makes up approximately 0.2% of Greenwoods Asset Management Ltd’s portfolio, making the stock its 16th biggest position. Greenwoods Asset Management Ltd owned about 0.06% of China Biologic Products worth $1,866,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in CBPO. BlackRock Inc. boosted its holdings in shares of China Biologic Products by 694.1% in the 1st quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock valued at $151,007,000 after buying an additional 1,318,183 shares in the last quarter. Schroder Investment Management Group boosted its holdings in shares of China Biologic Products by 771.5% in the 2nd quarter. Schroder Investment Management Group now owns 544,676 shares of the biopharmaceutical company’s stock valued at $60,845,000 after buying an additional 482,175 shares in the last quarter. FMR LLC boosted its holdings in shares of China Biologic Products by 27.5% in the 1st quarter. FMR LLC now owns 1,880,549 shares of the biopharmaceutical company’s stock valued at $188,300,000 after buying an additional 406,105 shares in the last quarter. Macquarie Group Ltd. bought a new stake in shares of China Biologic Products in the 1st quarter valued at about $27,324,000. Finally, Artisan Partners Limited Partnership boosted its holdings in shares of China Biologic Products by 103.2% in the 1st quarter. Artisan Partners Limited Partnership now owns 395,578 shares of the biopharmaceutical company’s stock valued at $39,609,000 after buying an additional 200,868 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

A number of research firms have recently weighed in on CBPO. Zacks Investment Research cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Monday, August 7th. BidaskClub cut shares of China Biologic Products from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Jefferies Group LLC restated a “buy” rating on shares of China Biologic Products in a report on Friday, August 4th. Finally, Goldman Sachs Group, Inc. (The) began coverage on shares of China Biologic Products in a report on Tuesday, May 30th. They issued a “neutral” rating on the stock. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. China Biologic Products has an average rating of “Hold” and a consensus price target of $132.00.

Shares of China Biologic Products, Inc. (CBPO) traded down 5.30% during trading on Friday, hitting $90.81. 849,154 shares of the company traded hands. China Biologic Products, Inc. has a 52-week low of $88.25 and a 52-week high of $126.47. The company has a 50-day moving average of $93.66 and a 200-day moving average of $104.09. The stock has a market capitalization of $2.47 billion, a PE ratio of 23.64 and a beta of 1.75.

China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.05. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The company had revenue of $89.28 million during the quarter, compared to analysts’ expectations of $97.33 million. During the same quarter in the previous year, the business earned $1.26 earnings per share. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. Equities analysts expect that China Biologic Products, Inc. will post $4.96 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/17/china-biologic-products-inc-cbpo-stake-maintained-by-greenwoods-asset-management-ltd.html.

China Biologic Products Company Profile

Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products, Inc. (NASDAQ:CBPO).

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Stock Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related stocks with our FREE daily email newsletter.